Uppsala, Sweden, 2011-06-10 08:48 CEST (GLOBE NEWSWIRE) -- THE FISCAL YEAR May 2010 – April 2011
· Consolidated Net sales amounted to TSEK106 (30 741)[1]
· Operating income amounted to TSEK -64 353 (-14 961)
· Net income after tax amounted to TSEK -65 960 (-17 054)
· Earnings per share amounted to SEK -1,50 (-0,47)
· Comprehensive income amounted to TSEK -65 960 (-17 054)
· An agreement was closed with Baxter Oncology for future commercial production
· An application for registration of Paccal® Vet was submitted in EU and USA
· The share was listed at NASDAQ OMX Stockholm and at Frankfurt Stock Exchange
THE FOURTH QUARTER February 1 - April 30, 2011
· Consolidated Net sales amounted to TSEK 0 (5 505)
· Operating income amounted to TSEK -21 764 (-5 187)
· Net income after tax amounted to TSEK -21 513 (-5 387)
· Earnings per share amounted to SEK -0,41 (-0,14)
· Comprehensive income amounted to TSEK -21 513 (-5 387)
EVENTS AFTER CLOSING DAY
License agreement signed for Paclical® in Israel and Turkey
[1] The numbers in parentheses concerns results for the corresponding period previous year
Head of Public Relations Maria Lundén, Tel +46 18 50 54 40 e-mail: press@oasmia.com www.oasmia.com
